Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs.